Johnson & Johnson (JNJ)
263.81
-3.80
(-1.42%)
USD |
NYSE |
Oct 23, 16:00
263.85
+0.04
(+0.02%)
Pre-Market: 20:00
Johnson & Johnson Enterprise Value : 662.44B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 662.44B |
| October 22, 2026 | 671.59B |
| October 21, 2026 | 647.93B |
| October 20, 2026 | 651.73B |
| October 19, 2026 | 638.33B |
| October 16, 2026 | 642.59B |
| October 15, 2026 | 637.10B |
| October 14, 2026 | 638.61B |
| October 13, 2026 | 625.86B |
| October 12, 2026 | 662.25B |
| October 09, 2026 | 656.74B |
| October 08, 2026 | 644.80B |
| October 07, 2026 | 649.54B |
| October 06, 2026 | 640.71B |
| October 05, 2026 | 636.26B |
| October 02, 2026 | 643.72B |
| October 01, 2026 | 650.05B |
| September 30, 2026 | 664.68B |
| September 29, 2026 | 672.65B |
| September 28, 2026 | 683.20B |
| September 25, 2026 | 681.44B |
| September 24, 2026 | 680.14B |
| September 23, 2026 | 676.50B |
| September 22, 2026 | 676.55B |
| September 21, 2026 | 677.22B |
| Date | Value |
|---|---|
| September 18, 2026 | 678.48B |
| September 17, 2026 | 679.03B |
| September 16, 2026 | 671.95B |
| September 15, 2026 | 671.76B |
| September 14, 2026 | 669.64B |
| September 11, 2026 | 667.86B |
| September 10, 2026 | 669.71B |
| September 09, 2026 | 671.47B |
| September 08, 2026 | 676.38B |
| September 04, 2026 | 691.09B |
| September 03, 2026 | 698.80B |
| September 02, 2026 | 691.05B |
| September 01, 2026 | 681.37B |
| August 31, 2026 | 668.51B |
| August 28, 2026 | 673.78B |
| August 27, 2026 | 668.31B |
| August 26, 2026 | 678.50B |
| August 25, 2026 | 686.06B |
| August 24, 2026 | 685.82B |
| August 21, 2026 | 679.08B |
| August 20, 2026 | 672.17B |
| August 19, 2026 | 686.71B |
| August 18, 2026 | 681.17B |
| August 17, 2026 | 660.12B |
| August 14, 2026 | 655.26B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.245T |
| Merck & Co., Inc. | 405.39B |
| Pfizer Inc. | 222.94B |
| Bristol Myers Squibb Co. | 159.59B |
| Abbott Laboratories | 207.10B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 210.00M |
| Revenue (Quarterly) | 25.40B |
| Total Expenses (Quarterly) | 25.19B |
| EPS Diluted (Quarterly) | 0.0858 |
| Gross Profit Margin (Quarterly) | 68.11% |
| Profit Margin (Quarterly) | 0.83% |
| Earnings Yield | 2.50% |
| Operating Earnings Yield | 3.98% |
| Normalized Earnings Yield | 3.515 |